Trade Autolus Therapeutics PLC - AUTL CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.05
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$1.08)Trade size with leverage ~ $5,000.00Money from leverage ~ $4,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.03)Trade size with leverage ~ $5,000.00Money from leverage ~ $4,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$1.08)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.03)

Key Stats

• Prev. Close: 1.52
• Open: 1.5
• 1-Year Change: -39.02%
• Day's Range: 1.45 - 1.51

Trade Autolus Therapeutics PLC - AUTL

What is Autolus Therapeutics PLC (AUTL)?

Autolus Therapeutics PLC is a biopharmaceutical company specializing in the development of next-generation programmed T cell therapies for the treatment of cancer. The company focuses on engineering T cells to recognize and destroy cancer cells by leveraging advanced synthetic biology techniques. Autolus's pipeline includes multiple candidates targeting hematological malignancies and solid tumors, utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. The company operates in research, development, and manufacturing of cell therapies, aiming to improve treatment outcomes for patients with difficult-to-treat cancers. Autolus collaborates with academic institutions and industry partners to advance its therapeutic programs. Its operations encompass clinical trials, regulatory engagement, and production of cell therapy products under stringent quality standards. The company is headquartered in the United Kingdom and maintains facilities for research and development activities. Autolus Therapeutics contributes to the evolving field of immuno-oncology by advancing cellular immunotherapies designed to harness the body's immune system against cancer.

Autolus Therapeutics PLC Stock Price Today: Live Overview

The price today is shaped by ongoing trading, with Autolus Therapeutics PLC trading at $1.54. Its intraday price fluctuated from $1.45 to $1.53, reflecting a daily move of -1.3158%.

FAQ: Autolus Therapeutics PLC (AUTL)

What is the current price of AUTL stock?

The last traded price is $1.54.

Does AUTL pay dividends?

Dividends are not paid by this company.

Does AUTL have a formal corporate presence or regional headquarters in the UAE?

Autolus Therapeutics PLC has no official regional office or subsidiary in the UAE and operates through partners only.

What is AUTL best known for?

The company is most famous for its development of engineered T-cell therapies for cancer.

What assets are typically shown together with AUTL?

Commonly shown alongside AUTL: Trelleborg, Bank Of China, iShares Global Consumer Discretionary ETF